We are live on
!
Find out more
AP
AtonRa Partners Portfolio holdings
AUM
$50.2M
1-Year Est. Return
47.76%
This Fund
S&P 500
This Quarter
Est. Return
+12.94%
1 Year Est. Return
+47.76%
3 Year Est. Return
+48.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$48.5M
(+22%)
Cap. Flow
+$27.1M
Cap. Flow
% of AUM
9.94%
Top 10 Holdings %
Top 10 Hldgs %
21.2%
Holding
121
New
13
Increased
46
Reduced
53
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SolarEdge
SEDG
|
+$3.1M |
| 2 |
Marvell Technology
MRVL
|
+$3.02M |
| 3 |
Veeva Systems
VEEV
|
+$2.97M |
| 4 |
Quanterix
QTRX
|
+$2.96M |
| 5 |
SoFi Technologies
SOFI
|
+$2.56M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Guardant Health
GH
|
+$2.98M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$2.86M |
| 3 |
Illumina
ILMN
|
+$2.18M |
| 4 |
Regenxbio
RGNX
|
+$2.05M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$1.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 44.35% |
| 2 | Healthcare | 32.32% |
| 3 | Financials | 8.79% |
| 4 | Industrials | 7.11% |
| 5 | Consumer Discretionary | 3.86% |
Similar funds
JCI
SC
AOGP
ACJ
UFG
KC
P
AMC
AtonRa Partners's Q2 2021 Portfolio in Review
As of Q2 2021, AtonRa Partners held 121 positions worth $273M, up 22% from $224M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
AtonRa Partners deployed $27.1M of net new capital in Q2 2021, opening 13 new positions and adding to 46 existing holdings. Its largest new stake was Marvell Technology: 61,809 shares worth $3.6M.
By sector, the portfolio is most concentrated in Technology at 44% of assets, up from 41% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Guardant Health, an estimated $2.98M trimmed.
- AtonRa Partners's largest Q2 2021 buy was Marvell Technology: 61,809 shares worth $3.6M.
- AtonRa Partners added most to SolarEdge in Q2 2021, an estimated $3.1M increase.
- AtonRa Partners's biggest Q2 2021 reduction was Guardant Health, cutting an estimated $2.98M.
- AtonRa Partners fully exited Vertex Pharmaceuticals in Q2 2021, selling an estimated $2.86M.
- AtonRa Partners's ten largest holdings make up 21% of its $273M portfolio in Q2 2021.
- AtonRa Partners opened 13 new positions and closed 9 in Q2 2021.
- AtonRa Partners's portfolio value rose 22% quarter-over-quarter to $273M.
Based on AtonRa Partners's 13F filing for Q2 2021, filed 12 Aug 2021.